Taking advantage of the strong hydrophobicity of the anticancer drug camptothecin (CPT), the CPT molecule was conjugated to a class of low-molecular-weight (MW) poly(ethylene glycol) (PEG) chains (MW = 500, 1000, and 2000), forming an amphiphilic prodrug. The CPT-PEG prodrug formed stable hydrogels based on a combination of the partial inclusion complexation between one end of the PEG blocks and α-CD and the hydrophobic aggregation of CPT groups. Meanwhile, the formed hydrogels could be loaded with water-soluble drug 5-fluorouracil (5-FU), which is always combined with CPT drugs to enhance their anticancer activity. Moreover, the hydrogel systems demonstrate unique structure-related reversible gel-sol transition properties at a certain temperature due to the reversible supramolecular assembly, and the gel-sol transition temperature could be modulated by varying the length of the PEG chain and the concentrations of α-CD, demonstrating the possibility of achieving on-demand gel-sol transitions. The structure-related reversible gel-sol transition properties were proved by rheological property, XRD, DSC, and SEM measurements. The different controlled release profiles of two different anticancer drugs showed significant temperature-dependent properties. This easily prepared supramolecular hydrogel with excellent biocompatibility and tunable temperature responsiveness has significant potential for controlled drug release applications.
No takes yet. Share an insight, caveat, or question.
Ha et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: